Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
ALAMEDA, Calif., Sept. 20, 2016 -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at 5:30 p.m. ET/ 2:30 p.m. PT. The conference will be held at the Encore at Wynn Hotel in Las Vegas.
A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website.
About OncoCyte Corporation
OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.
Investor Contact: EVC Group, Inc. Michael Polyviou/Amanda Prior 646-445-4800 [email protected] /[email protected]
